文献速递中枢神经肿瘤放疗放疗物理与技术

ClonoScreen3D——一种用于鉴定胶质母细胞瘤放射增敏剂的新型三维克隆形成筛查平台

ClonoScreen3D - A Novel 3-Dimensional Clonogenic Screening Platform for Identification of Radiosensitizers for Glioblastoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-03-16

研究评估三维克隆形成筛查平台ClonoScreen3D用于筛选胶质母细胞瘤(GBM)放射-药物组合的效用,以金标准克隆存活为读出。PARP抑制剂他拉唑帕利、芦卡帕利和奥拉帕利均显示与辐射显著交互并被确认是真正的放射增敏剂;DNA损伤应答抑制剂面板中13/15个化合物与辐射显著交互;dinaciclib和cytarabine显示单药活性及先前未报告的辐射交互(辐射交互比分别为1.28和1.90),并在全克隆形成实验中验证为放射增敏剂(增敏增强比分别为1.47和1.35)。

要点

  • ClonoScreen3D以金标准克隆存活为读出,可定量单药活性(EC50)和药物-辐射交互(辐射交互比)。
  • PARP抑制剂他拉唑帕利、芦卡帕利和奥拉帕利经ClonoScreen3D显示与辐射显著交互,并被全克隆形成实验确认为真正的放射增敏剂。
  • dinaciclib和cytarabine的辐射交互比分别为1.28和1.90,全克隆形成实验增敏增强比分别为1.47和1.35。

核心结论

  • ClonoScreen3D平台被证明是筛选单药活性和辐射-药物组合活性的稳健方法,使用金标准克隆形成性,该实验是鉴定放射增敏剂的工具。
  • 作者预计该技术将加速鉴定具有真正转化价值的新型放射-药物组合。

研究设计与样本

  • 研究使用患者来源的GBM细胞系,优化后纳入96孔板三维克隆形成筛查平台ClonoScreen3D。
  • 该系统中GBM细胞的辐射反应高度可重复,并与低通量三维实验中观察到的结果相当。

主要发现

  • PARP抑制剂他拉唑帕利、芦卡帕利和奥拉帕利经ClonoScreen3D显示与辐射显著交互,随后被全克隆形成实验确认为真正的放射增敏剂。
  • 筛查DNA损伤应答抑制剂面板显示这些化合物与辐射显著交互的预期倾向(13/15个化合物)。
  • 第二次筛查评估靶向转录组分析所识别通路的化合物面板,显示dinaciclib和cytarabine的单药活性及先前未报告的辐射交互(辐射交互比分别为1.28和1.90)。
  • dinaciclib和cytarabine在全克隆形成实验中被验证为放射增敏剂(增敏增强比分别为1.47和1.35)。

关键数值与推荐

  • ClonoScreen3D提供候选药物单药活性定量(半数最大有效浓度即EC50)和药物与辐射之间交互的定量(辐射交互比)。
  • dinaciclib的辐射交互比为1.28,全克隆形成实验增敏增强比为1.47。
  • cytarabine的辐射交互比为1.90,全克隆形成实验增敏增强比为1.35。
  • DNA损伤应答抑制剂面板中13/15个化合物与辐射显著交互。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma (GBM) is a lethal brain tumor. Standard-of-care treatment comprising surgery, radiation, and chemotherapy results in median survival rates of 12 to 15 months. Molecular-targeted agents identified using conventional 2-dimensional (2D) in vitro models of GBM have failed to improve outcome in patients, rendering such models inadequate for therapeutic target identification. A previously developed 3D GBM in vitro model that recapitulates key GBM clinical features and responses to molecular therapies was investigated for utility for screening novel radiation-drug combinations using gold-standard clonogenic survival as readout. METHODS AND MATERIALS: Patient-derived GBM cell lines were optimized for inclusion in a 96-well plate 3D clonogenic screening platform, ClonoScreen3D. Radiation responses of GBM cells in this system were highly reproducible and comparable to those observed in low-throughout 3D assays. The screen methodology provided quantification of candidate drug single agent activity (half maximal effective concentration or EC50) and the interaction between drug and radiation (radiation interaction ratio). RESULTS: The poly(ADP-ribose) polymerase inhibitors talazoparib, rucaparib, and olaparib each showed a significant interaction with radiation by ClonoScreen3D and were subsequently confirmed as true radiosensitizers by full clonogenic assay. Screening a panel of DNA damage response inhibitors revealed the expected propensity of these compounds to interact significantly with radiation (13/15 compounds). A second screen assessed a panel of compounds targeting pathways identified by transcriptomic analysis and demonstrated single agent activity and a previously unreported interaction with radiation of dinaciclib and cytarabine (radiation interaction ratio 1.28 and 1.90, respectively). These compounds were validated as radiosensitizers in full clonogenic assays (sensitizer enhancement ratio 1.47 and 1.35, respectively). CONCLUSIONS: The ClonoScreen3D platform was demonstrated to be a robust method to screen for single agent and radiation-drug combination activity. Using gold-standard clonogenicity, this assay is a tool for identification of radiosensitizers. We anticipate this technology will accelerate identification of novel radiation-drug combinations with genuine translational value.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Jackson MR, Richards AR, Oladipupo AA, et al. ClonoScreen3D - A Novel 3-Dimensional Clonogenic Screening Platform for Identification of Radiosensitizers for Glioblastoma. Int J Radiat Oncol Biol Phys. 2024. PMID: 38493899. doi:10.1016/j.ijrobp.2024.02.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。